Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for healthcare industry professionals · Friday, July 20, 2018 · 456,112,863 Articles · 3+ Million Readers

Market Overview of Acute Myeloid Leukemia Research and Detailed Forecast 2026

Acute Myeloid Leukemia Pharmaceutical and Healthcare Pipeline Review

PUNE, INDIA, March 20, 2018 / -- Summary
Acute Myeloid Leukemia (AML) is a disease that has been characterized by a stagnant pipeline and, consequently, the treatment paradigm has not substantially changed over time. Since the 1970s, the standard of care in newly diagnosed fit patients has been a chemotherapy bases 7 + 3 induction regimen (seven days of cytarabine + three days of an anthracycline), aimed at achieving a complete hematologic remission (CR), followed by consolidation therapy with cytarabine, or an allogeneic hematopoietic cell transplantation (HCT). In the last decade, a better understanding of the molecular basis of AML has encouraged the development of new targeted therapies, and this led to the launch of the first targeted agents in 2017. The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the AML space, including regulatory, commercial, and clinical events as well as understand how all of these events will impact the projected market forecast.


Key events covered in the Dynamic Market Forecast include -
- Regulatory filings
- Approval decisions
- Pricing changes
- Patent litigation
- Clinical trial data announcements
- Clinical trial failures
- Clinical trial timeline updates

Components of the slide deck include -
- Timeline of market-impacting events
- Key clinical trial landscape updates
- Conference coverage
- Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective
- Overview of updates to the forecast model based on anticipated future impact of events
- Forward-looking events calendar listing expected key updates to the AML competitive space through December 2018

Reasons to buy
- Recent Regulatory Events
- Recent Commercial Events
- Recent Clinical Events
- New SOC expected for elderly t-AML and AML-MRC patients
- Adoption of the First FLT3 Inhibitor, Rydapt, in the US and EU
- Lack of Competition in the IDH+ AML Market Segment Benefits Celgene and Agios
- US Approval of the First CD33 Targeting Agent, Mylotarg

Table of Content: Key Points
1. Dynamic Market Forecast Overview 6
1.1 Related Reports 7
1.2 Upcoming Related Reports 8
2. Executive Summary 9
2.1 Key Updates to AML Market Dynamics 10
2.2 Key Events in Update 11-12
2.3 Updates to Treatment Algorithms 13-14
2.4 Updates to Pipeline Competitive Assessment 15-16
2.4 Market Insight on Key Events 17
3. Conference Coverage - ASH 2017
3.1 Selected Abstracts ASH2017 - AML 19-20
4. Event 1: New SOC expected for elderly t-AML and AML-MRC patients
4.1 Key Updates to the Frontline Setting - Elderly Patients 22
4.2 Jazz, Vyxeos (CPX-351) 23-24
4.3 What Do Physicians Think? 25
4.4 Summary/Trends 26
4.5 Sources 27
5. Event 2: Adoption of the First FLT3 Inhibitor, Rydapt, in the US and EU
5.1 Key Updates About the Use of FLT3 Inhibitors in the First- Line Setting 29
5.2 Competitive Landscape of FLT3 Inhibitors in AML 30
5.3 Novartis, Rydapt (midostaurin) 31
5.4 What Do Physicians Think? 32
5.5 Arog, crenolanib 33
5.6 Astellas, gilteritinib 34
5.7 What Do Physicians Think? 35
5.8 Summary/Trends 36
5.9 Sources 37
6. Event 3: Lack of Competition in the IDH+ AML Market Segment Benefits Celgene and Agios
6.1 Key Updates in IDH+ AML 39
6.2 Agios/Celgene, Idhifa 40-41
6.3 Agios, ivosidenib 42-44


Get in touch:

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here

Powered by EIN Presswire